| 引用本文: | 冯新颖,李斌,陈换飞,朱韶峰.治疗中至重度斑块型银屑病新药：Risankizumab[J].中国现代应用药学,2021,38(20):2621-2624. |
| FENG Xinying,LI Bin,CHEN Huanfei,ZHU Shaofeng.New drug for Treatment of Moderate-to-severe Plaque Psoriasis: Risankizumab[J].Chin J Mod Appl Pharm(中国现代应用药学),2021,38(20):2621-2624. |
|
| 摘要: |
| 白细胞介素23（interleukin-23，IL-23）为一种天然存在的细胞因子，参与炎症和免疫反应。Risankizumab是一种人源性抗IL-23单克隆抗体，可特异性与IL-23 p19亚基结合，减少炎症反应的发生。2019年4月23日，美国食品药物监督管理局批准Risankizumab用于治疗成人中重度斑块型银屑病。Risankizumab治疗相关的不良事件主要包括上呼吸道感染、头痛、疲劳、注射部位反应和真菌感染，患者一般均可良好耐受。本文从作用机制、药动学、临床应用及不良反应等方面对Risankizumab进行综述。 |
| 关键词: Risankizumab 银屑病 白细胞介素23 |
| DOI：10.13748/j.cnki.issn1007-7693.2021.20.026 |
| 分类号:R977.1 |
| 基金项目: |
|
| New drug for Treatment of Moderate-to-severe Plaque Psoriasis: Risankizumab |
|
FENG Xinying, LI Bin, CHEN Huanfei, ZHU Shaofeng
|
|
Phase I Clinical Trials Centre, Luoyang Central Hospital Affliated to Zhengzhou University, Luoyang 471000, China
|
| Abstract: |
| Interleukin-23(IL-23) is a natural cytokine involved in inflammation and immune response. Risankizumab is a humanized anti-IL-23 monoclonal antibody, which can bind with high affinity to IL-23 p19 subunit, thereby inhibiting the inflammatory response. It was approved for the treatment of patients with moderate-to-severe plaque psoriasis by the U.S. Food and Drug Administration on April 23, 2019. The most common treatment-related adverse events include upper respiratory infections, headache, tiredness, injection site reactions, and fungal infections, and patients are generally well tolerated. This paper introduced risankizumab from the aspects of mechanism, pharmacokinetics, clinical application and adverse reactions. |
| Key words: Risankizumab psoriasis interleukin-23 |
